Meeting
2018 ASCO Annual Meeting
Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers.
Authors
Michael David Offin
Memorial Sloan Kettering Cancer Center, New York, NY
Michael David Offin , Hira Rizvi , Megan Tenet , Ai Ni , Francisco Sanchez Vega , Mark G. Kris , Charles M. Rudin , Gregory J. Riely , Helena Alexandra Yu , Matthew David Hellmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9042)
DOI
10.1200/JCO.2018.36.15_suppl.9042
Abstract #
9042
Poster Bd #
365
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.
First Author: Helena Alexandra Yu
Poster
2016 ASCO Annual Meeting
Concurrent genetic alterations identified by next-generation sequencing in pre-treatment, metastatic EGFR-mutant lung cancers.
First Author: Helena Alexandra Yu
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse